ArticleFrontiers in pediatrics2026
Serum beta-2 microglobulin as a diagnostic biomarker for pediatric Epstein-Barr virus infections: a retrospective study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate serum beta-2 microglobulin (β2M) as a diagnostic biomarker for acute primary Epstein-Barr virus (EBV) infection in children, Additionally, serum vitamin D3 levels were compared between EBV-infected children and children with viral upper respiratory tract infection to explore their potential clinical relevance. Methods: A total of 129 children with acute primary EBV infection were identified as the EBV group, while 130 children with viral upper respiratory tract infections in the same age group hospitalized during the same period were identified as the control group. The age, gender, and laboratory indicators of the two groups were analyzed and compared. Pearson's correlation was used to analyze the correlation between β2M and serum EBV-DNA concentration. The receiver operating characteristic (ROC) curve was drawn, and the threshold and area under the curve (AUC) of β2M for predicting the diagnosis of EBV infection were calculated. Results: The white blood cell count, serum lactate dehydrogenase, and alanine aminotransferase levels in the EBV group were significantly than those in the control group ( Conclusion: The serum β2M levels are significantly increased in the stage of primary EBV infection in children, and β2M appears to be a promising biomarker for predicting primary EBV infection. The serum vitamin D3 levels are significantly reduced in children with primary EBV infection, and the protective effect of vitamin D supplementation in those children warrants additional clinical exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.